News

Some Candida albicans yeast strains may damage the gut of patients with inflammatory bowel disease, according to a new study, suggesting a possible way to tailor treatments to individual patients in the future.

A new vaccine developed at MIT and Beth Israel Deaconess Medical Center may aid in efforts to vaccinate certain parts of the world, offering an inexpensive, easy-to-store and effective alternative to RNA vaccines.

An enzyme from a bacteria that commonly contaminates cell culture has been shown to produce a novel biodegradable polymer that could be used for drug delivery and tissue engineering.

Children who develop type 1 diabetes show epigenetic changes in the cells of their immune system already before the antibodies of the disease are detected in their blood. The findings of two new studies offer new opportunities to identify the children with the genetic risk for developing diabetes very early on.

According to a study, tumors can use an enzyme called ART1 to thwart antitumor immune cells, making the enzyme a promising new target for immunity-boosting cancer treatments.

Researchers describe the first system that enables two unrelated organisms to communicate.

In a study, P. aeruginosa worked with fluconazole to eliminate drug tolerance and clear a C. albicans infection.

Scientists have discovered a cellular mechanism that may yield insights into improving vaccines and better understanding cancer and autoimmune diseases.

Research suggests that the parasites that cause cutaneous leishmaniasis may have met their match in vaccines developed using CRISPR.

Researchers have formed lymphoid follicles in a microfluidic Organ Chip device that replicate human immune functions and vaccine responses in vitro.